The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VOR | -1.88% | N/A | N/A | -97% |
| S&P | +13.96% | +91.24% | +13.85% | +76% |
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.
No news articles found for Vor Biopharma.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$2.10M | -133.3% |
| Market Cap | $203.55M | 198.4% |
| Market Cap / Employee | $1.28M | 0.0% |
| Employees | 159 | -5.4% |
| Net Income | -$1,573.67M | -5552.7% |
| EBITDA | -$272.18M | -867.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $192.99M | 153.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -959.44% | -899.3% |
| Return On Invested Capital | -57.28% | 9.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$35.34M | -61.7% |
| Operating Free Cash Flow | -$35.18M | -61.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.66 | 1.43 | 1.36 | -0.14 | -124.39% |
| Price to Tangible Book Value | 9.76 | 20.89 | 18.52 | 61.23 | 452.15% |
| Enterprise Value to EBITDA | -0.65 | -0.58 | -1.86 | 0.00 | -100.02% |
| Return on Equity | -78.1% | -90.8% | -94.5% | -125.4% | 84.26% |
| Total Debt | $32.85M | $31.83M | $30.78M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
